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Abstract
Background: Plasmodium vivax is divided into two subtypes, a dominant form, VK210 and a variant form, VK247.
This division is dependent on the amino acid composition of the circumsporozoite (CS) protein. In this study, the
prevalence of the VK247 variant form of P. vivax was investigated in Myanmar.
Methods: The existence of malaria parasites in blood samples was determined by microscopic examination,
polymerase chain reaction (PCR) and DNA hybridization assays. To test for antibodies against P. vivax and
Plasmodium falciparum in blood samples, an indirect immunofluorescence antibody test (IFAT) was performed
using asexual blood antigens. An enzyme-linked immunosorbent assay with synthetic VK210 and VK247 antigens
was carried out to discriminate between the P. vivax subtypes.
Results: By thick smear examination, 73 (n = 100) patients were single infected with P. vivax, one with P.
falciparum and 13 with both species. By thin smear, 53 patients were single infected with P. vivax, eight with only
P. falciparum and 16 with both. Most of the collected blood samples were shown to be P. vivax positive (n = 95)
by PCR. All cases that were positive for P. falciparum by PCR (n = 43) were also positive for P. vivax. However, 52
cases were single infected with P. vivax. IFAT showed antibody titres from 1:32 to 1:4,096. Additionally, using
specific antibodies for VK210 and VK247, ELISA showed that 12 patients had antibodies for only the VK210 subtype,
4 patients had only VK247 subtype antibodies and 21 patients had antibodies for both subtypes. Using a DNA
hybridization test, 47 patients were infected with the VK210 type, one patient was infected with VK247 and 23
patients were infected with both subtypes.
Conclusions: The proportion of the VK247 subtype in Myanmar was 43.1% (n = 25) among 58 positive cases by
serodiagnosis and 25.6% (n = 24) among 94 positive cases by genetic diagnosis. In both diagnostic methods, the
infection status of malaria patients is highly diverse with respect to malaria species, and multiple clonal infections
are prevalent in Myanmar. Therefore, the complexity of the infection should be considered carefully when
diagnosing malaria in Myanmar.
Background
Plasmodium vivax, a causative agent of relapsing benign
tertian malaria, is the second most important malaria-
causing species and afflicts several hundred million
people annually [1]. Malaria constitutes a major health
problem and is deeply associated with socioeconomic
burden in many temperate and most tropical countries.
In Myanmar, malaria is ranked as the number one pub-
lic health problem, and nearly6 0 0 , 0 0 0m a l a r i ap a t i e n t s
seek medical attention at health institutions annually.
Among malaria species in Myanmar, Plasmodium falci-
parum accounts for 80% of infections, P. vivax accounts
for 17.8% of infections and the remaining are due to
Plasmodium malariae with mixed infections [2].
The surface membrane of all plasmodial sporozoites is
covered by an antigen designated as circumsporozoite
(CS) protein. The CS proteins have a central immuno-
dominant region, consisting of tandemly repeated short
amino acid sequences, which contain multiple copies of
the immunodominant B cell epitope [3]. Because they
are highly immunogenic and can induce a protective
response in sporozoite-immunized experimental animals
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candidates for a human malaria vaccine. These immuno-
dominant B cell epitopes within a large number of
P. falciparum isolates of diverse geographical origin, and
as m a l l e rn u m b e ro fP. vivax isolates were examined
and found to be conserved within the species [4]. A
strain of P. vivax containing a variant repeat in its CS
protein was first isolated in Thailand [5]. The CS repeat
of this variant strain (Thai VK247) differs at 6/9 amino
acids within the repeat sequence found in all previously
described P. vivax CS protein. Following this discovery,
several studies have been conducted to evaluate the glo-
bal distribution of variant VK247; it was detected in
indigenous populations of China [6], Brazil [7], Mexico
[8,9], Peru [9,10], and Papua New Guinea [8].
It is known that the drug susceptibility of the VK247
subtype of P. vivax is slightly different than VK210 [11],
as well as that Anopheles albimanus and Anopheles
pseudopunctipennis differ in their susceptibilities to
P. vivax circumsporozoite phenotypes. Anopheles albi-
manus is more susceptible to the VK210 subtype,
whereas An. pseudopunctipennis is more susceptible to
the VK247 subtype [12].
Here, the frequency of the two CSP variants (VK210
and VK247) in wild P. vivax isolates collected in Yangon
and Mandalay, Myanmar was determined by ELISA and
DNA hybridization. This effort may be useful for updat-
ing the anti-malarial control programme in Myanmar.
Methods
Study areas and blood collection of clinical isolates of
malaria
Patients attending the Central VBDC (Vector Borne Dis-
eases Control) clinic in Yangon and Wet-Won station
hospital (Pyin Oo Lwin District) in Mandalay, Myanmar
in January 2000 were selected for this study. All of the
individuals exhibited clinical symptoms associated with
malaria. Thin and thick blood smears were prepared
from the blood collected for microscopic examination
(magnification 7 × 100) from the fingertips of indivi-
duals. A local health unit employee read the Giemsa-
stained thick blood smears in the fields, and treatment
was administered to those individuals who tested posi-
tive for malaria, based on the guidelines of The Depart-
ment of Health, the Union of Myanmar. And thin blood
smears were examined by co-authors in laboratory con-
dition. Before treatment, additional blood samples of
approximately 3 ml were collected from each individual
whose infection was confirmed by microscopic examina-
tion (n = 100). The blood samples were transferred to
the National Institute of Health, Korea Centers for Dis-
ease Control and Prevention, Korea, for further poly-
merase chain reaction (PCR), DNA hybridization
genotyping, and antibody analysis. Informed consent
was obtained from all patients. The study protocol was
approved by the Department of Health (Upper Myan-
mar), the Union of Myanmar.
Amplification of CS the protein gene
For the purpose of preparing variant CS protein genes,
genomic DNA was extracted from the whole blood of a
malaria patient using the QIAamp Blood Kit (Qiagen
Co., Hilden, Germany). PCRs were performed with the
AccuPower PCR Premix (Bioneer Co., Taejeon, Korea),
50 ng of purified genomic DNA, 40 pmoles each for-
ward (F1; 5′-TCCCCACGCACTGCGGGCACAAT-3′)
and reverse primers (R1; 5′-TTAATATGCACCGTGAG-
GACGCC-3′), and the total volume was adjusted to 20
μl with distilled water. The F1 primer contained several
nucleotides of the signal peptide and the first 4 amino
acids of the mature protein. The R1 primer contained
the region starting 21 bases downstream of the stop
codon so that this primer set would amplify the entire
mature CS protein gene. The cycling conditions were
performed as follows: denatured at 94°C for 5 min; 35
cycles of 1 min at 94°C, 1 min at 49°C, 2 min at 72°C;
and a final incubation at 72°C for 5 min. A second PCR
performed under the same conditions except that the
PCR products (2-5 μl) were added instead of genomic
DNA and that different forward (F2; 5′-AAAAAG-
GATGGAAAGAAAG-3′)a n dr e v e r s e( R 2 ;5 ′-
GACTTTTCATTTGGGGCA-3′)p r i m e r sw e r ei n c l u d e d
in the reaction [13]. To exclude the blood samples that
were co-infected with P. falciparum, PCRs were per-
formed with a P. falciparum specific primer set that
amplifies the ring-infected erythrocyte surface antigen
(RESA), as described by Wooden et al [forward (5′-
GATCAAGGAGGAGAGAACC-3′)a n dr e v e r s e( 5 ′-
CAGCATTAACACCAACACC-3′)] [14]. All the PCR
products were analysed on a 1.2% agarose gel, confirmed
under UV transillumination and purified with the
NucleoSpin Extract kit (Macherey-Nagel, Duren, Ger-
many). The purified PCR products were ligated with the
pCR2.1 cloning vector (Invitrogen Co., Carlsbad, CA,
USA) and then transformed into E. coli INVaF’ accord-
ing to the procedures of Invitrogen.
Genotyping of PCR products by DNA hybridization
Half of the 20 μl PCR products was blotted onto a nylon
membrane by a slot blotter. Two oligonucleotides,
AL116 (5′-GGTGATAGAGCAGATGGA-3′) for VK210
type and AL114 (5′-ATCAACCAGGAGCAAATG-3′)
for VK247 type, were used as probes in DNA hybridiza-
tion [15]. These probes were end-labeled with
35S-a-
dATP using a 3′-end labeling kit (Amersham Pharmacia
Biotech, Uppsala, Sweden) for 1 hr at 37°C. The radiola-
beled oligonucleotides were separated from unincorpo-
rated nucleotides on a Sephadex column (Amersham
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10 min in denaturation buffer and washed with distilled
water, and then incubated with freshly prepared neutra-
lization buffer two times for 15 min. After incubating
the nylon membranes in 5× SSC (0.75 M sodium chlor-
ide and 0.075 M sodium citrate) for 5 min, the mem-
branes were pre-hybridized for 1 hr at 42°C in 5× SSC,
1% SDS, 1× Denhart’s solution (1% BSA, 1% Ficoll 400,
and 1% polyvinyl pyrrolidone), and 5% sodium pyropho-
sphate. Hybridizations were performed in the same buf-
fer with radiolabeled nucleotides for 12 hrs at 42°C.
Each nylon membranes was co-reacted with anti-AL116
(5′-CCACTATCTCGTCTACCT-3′) and anti-AL114 (5′-
TAGTTGGTCCTCGTTTAC-3′) for positive controls.
After hybridization, nylon membranes were washed
three times for 5 min each at 42°C in 5× SSC and 1%
sodium pyrophosphate. These nylon membranes were
air-dried and exposed to X-ray film (Kodak X-Omat,
Sigma, St. Louis, MO, USA) with an intensification
screen at -80°C for 72 hrs.
DNA sequencing and analysis
After genotyping P. vivax, several candidates that could
contain the variant CS protein gene were selected for
DNA sequencing. After gel extraction with a Qiagen gel
extraction kit, PCR products were ligated into the
pCR2.1 cloning vector and transformed into Escherichia
coli INVaF’. The PCR product inserted into E. coli was
selected on ampicillin and 5-bromo-4-chloro-3-indolyl
b-D-galactopyranoside (X-gal) containing medium. To
determine whether the proper DNA was in E. coli,
restriction enzyme digestion was done with EcoRI after
plasmid isolation with a Qiagen plasmid isolation kit
according to the method supplied by manufacture. The
variant CS protein gene sequence was determined using
the ABI PRISM dye terminator cycle sequencing ready
reaction kit FS (Perkin Elmer, Cambridge, MA, USA)
according to the supplied manual. M13 reverse and
M13 forward (-20) primers were used in sequencing.
Nucleotide and deduced amino acid sequences were
analysed using EditSeq and Clustal in the Megalign pro-
gram, and the multiple alignment programs in the
DNASTAR package (DNASTAR, Madison, WI, USA).
The internet-based BLAST search program of the
National Center for Biotechnology Information (NCBI)
was used to search protein databases.
Indirect immunofluorescence antibody test
To test for antibodies against malaria, an indirect immu-
nofluorescence antibody test (IFAT) was performed with
whole blood antigens for P. vivax and P. falciparum as
described by Sulzer et al [ 1 6 ] .B r i e f l y ,1 0m lo fm a l a r i a
parasite infected blood was collected by venopuncture
from P. vivax and P. falciparum patients. After
removing the plasma, the cells were suspended in phos-
phate buffered saline (PBS, pH 7.2) and centrifuged for
5 min at 2,500 rpm. The supernatant was discarded the
cells were suspended in fresh PBS and the wash step
was repeated three more times. Finally, an appropriate
amount of PBS was added to maintain the parasitaemia
at no less than 1%. The cells were dropped onto each
well of Teflon coated slides. After drying them in room
temperature for 12 hrs, the slides were kept at -70°C
until required. To determine the antibody titres of each
patient against P. vivax and P. falciparum,t h ea n t i g e n
slides were fixed in pre-cooled acetone (-20°C) for 10
min, washed with PBS and added 20 μld i l u t e ds e r a
from 1:32 to 1:8,192 (vol/vol) was added to each well.
The positive and negative controls were dropped on
each slide and incubated in a moisture chamber for 30
min at 37°C. The reactions were stopped by washing
out the reacted sera with PBS. The slides were
immerged in PBS for 6 min and then dried at room
temperature. Diluted FITC conjugated anti-human IgG
(Sigma, 1:32 vol/vol in PBS) was added to each well and
incubated and washed using the same method described
above. Then several drops of buffered glycerol were
added to the samples and covered with coverslips. The
slides were examined under a 40× fluorescence
objective.
Enzyme-linked immunosorbent assay
To verify that the blood samples had antibodies against
the synthetic VK210 and VK247 antigens obtained from
R.A Wirtz (Centers for Disease Control and Prevention,
Atlanta, GA, USA), an enzyme-linked immunosorbent
assay was performed with these antigens. Briefly, 50 μl
of capture antigen solution (1 μla n t i g e n / 5 0μl) was
placed in a 96-well plate (Corning, Lowell, MA, USA)
and incubated for 12 hrs at room temperature. The cells
were aspirated and filled with blocking buffer (1% BSA,
0.05% PBS-Tween 20) and incubated for 1 hr at room
temperature. After washing the wells with 0.05% PBS-
Tween 20 three times, the human serum samples in
blocking buffer at a dilution of 1:100 (vol/vol) were
added to each of the wells. The four positive and four
negative control serum samples were also added to each
plate. After a 2-hr incubation at room temperature, the
plates were washed with 0.05% PBS-Tween 20 three
times and then the peroxidase conjugated anti-human
IgG (Sigma, 1:2,000, vol/vol) diluted in blocking buffer
was added and incubated again for 1 hr at room tem-
perature. The reaction was completed by washing the
plates as described above. To develop the color, 100 μl
of 2.2’-azino-di-(3-ethyl-benzthiozoline-6-sulfonic acid)
(ABTS) peroxidase substrate (Kirkegaard & Perry
Laboratories, Gaithersburg, MD, USA) was added and
incubated for 30 min. The absorbance of the mixture
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taken as the mean ± 2 standard deviations of the nega-
tive samples.
Results
Characterization of each malaria parasite
To confirm malaria parasite infection from symptomatic
patients, thin blood films were examined in fields and
thin blood films were examined in the laboratory. As a
results of the thick smear examination in the field,
73 patients (n = 100) were found infected with P. vivax,
14 with P. falciparum, and 13 with both species. By thin
smear, 53 patients were infected with P. vivax,e i g h t
with P. falciparum and 16 with both species. Seven
p a t i e n t sw e r es h o w nt ob en e g a t i v eb yt h et h i ns m e a r
technique.
Most of the collected blood samples were shown to be
P. vivax positive (n = 95), and only five were negative by
PCR examination. All patients who had P. falciparum
also had P. vivax (n = 43). However, 52 patients were
infected only with P. vivax (Table 1).
In genotyping by DNA hybridization, 47 patients
showed a positive reaction with VK210 (dominant form)
specific probe, 23 patients were positive with both
probes, and only one patient was positive for the VK247
subtype (variant form) (Table 2).
Seroprevalence of malaria in Myanmar
When patient serum was analysed by IFAT that used
P. vivax or P. falciparum-infected red blood cells as
antigen, the titre against P. vivax ranged from 1:64 to
1:4,096. Ninety four patients showed high titre over
1:256 which represented current infection. Only six
cases showed under 1:128. Seven samples did not have
antibodies to P. falciparum, whereas the other samples
had titres ranging from 1:32 to 1:4,096. Antibody titres
of patients were distributed evenly rather than P. vivax
cases and sixty seven cases showed over 1:256 (Table 3).
With regards to the proportion of antibodies against
the variant form, 12 patients had antibodies for the
VK210 subtype only, 21 patients had them for both and
4 patients only had VK247 subtype antibodies. Of the
patients tested, 42 did not have any antibodies for either
subtype, even they showed positive reaction in IFAT
(Table 4).
Discussion
These studies demonstrated that parasite populations
are highly heterogenetic and provided insight into the
dynamics of disease transmission, which in turn drives
our knowledge on drug application and disease control.
Although Myanmar is one of the major malaria endemic
countries and contributes to approximately 60% of
malarial deaths in the South-East Asia region [2], the
genetic diversity of the malarial parasites circulating in
this county is poorly understood.
The P. vivax species contains two distinct polymorph-
isms, VK210 and VK247, which are widespread in
Southeast Asia and South America [5]. In areas where
two polymorphisms coexist, intrinsic biological differ-
ences between the polymorphs may affect their survival
[17]. Fluctuations in the proportion of mosquitoes
infected with the two polymorphs may reflect humoral
immune pressure on the VK247 strain [18]. Anopheles
albimanus was more susceptible to phenotype VK210
and less susceptible to phenotype VK247, whereas Ano-
pheles pseudopunctipennis was the opposite. Addition-
ally, the geographic distribution of the two polymorphs
in southern Mexico reflects the distribution of the Ano-
pheline mosquitoes, with patients living more than 170
m above sea level being infected with VK247 [19].
By microscopic examination, thick blood films can
find more patients (n = 100) than thin blood films (n =
93), and these results might originate from the relatively
small amount of blood used in the thin smear. Addition-
ally, this examination missed seven cases of infection.
However, we could determine malaria species more
clearly in the thin smear. In the case of PCR examina-
tion, all patients were infected with P. vivax, except for
Table 1 Detection of malaria parasites by PCR with
specific primers for P. vivax and P. falciparum
Pv
(Single)
Pf
(Single)
Pv + Pf
(Double)
Negative Total
52 0 43 5 100
Pv; Plasmodium vivax
Pf; Plasmoium falciparum
Table 2 Genotyping of P. vivax according to the
nucleotide composition of their CS protein genes
VK210
1
(Single)
VK247
2
(Single)
VK210+VK247
3
(Double)
Not obtained
4 Total
47 1 23 6 100
1; Patients who were infected with the Plasmodium vivax VK210 dominant
form
2; Patients who were infected with the Plasmodium vivax VK247 variant form
3; Patients who were infected with the Plasmodium vivax VK210 and VK247
form
4; Sample could not be examined due to poor PCR reactions.
Table 3 Antibody titers of patients in response to
P. vivax and P. falciparum asexual stage antigens
Reciprocal antibody titre
Negative 32 64 128 256 512 1,024 2,048 4,096 Total
Pv 0 0 1 5 11 18 36 24 5 100
Pf 7 2 13 11 10 14 12 18 13 100
Pv; Plasmodium vivax
Pf; Plasmoium falciparum
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infected only by P. falciparum: all were co-infected with
P. vivax and P. falcipaum (Table 1). Additionally,
positive rate in PCR was much higher than that of
microscopic examination. Therefore, it is highly recom-
mended that more intensive concentration is needed
when examining the blood films in field and laboratory
conditions. The fact that there were less P. falciparum
cases than P. vivax c a s e si sd u et ot h es e a s o no fb l o o d
sample collection, as P. vivax is predominant during the
winter season in Myanmar [2].
During CS protein genotyping of P. vivax,o n ec a s e
was infected with only VK247, the variant form. Most of
patients were infected with dominant form, VK210.
Even though one case was infected with VK247 subtype
only, a total of 23 cases (24.5%) were co-infected with
VK247 and VK210 (Table 2). A similar distribution pat-
tern of VK210 and VK247 mixed infections was
observed in Thailand (25.6%) [20]. Although, all the
cases of the variant form were not analysed, VK247 of
Myanmar has high homology with the Thai strain
(97.2%, GenBank accession No. U08983), it has a differ-
ent number of nonapeptide repeats (i.e., Thai strain has
18 times repeat of ANGA(G/D)(N/D)QPG but the
Myanmar strain has 19 repeats of AN(G/E)A(G/D)(N/
D)QPG. This isolate has a different amino acid repeat in
a third of the nonapeptide repeats, that is, usually the
third amino acid is conserved as G, which is translated
from GGA or GGG, however, in some of the repeats, it
has an E instead of G, which is translated from GAG
[5]. Interestingly, sporozoites carrying the VK247
sequence were more frequently produced in An. albima-
nus than sporozoites with the VK210 sequence [21].
Therefore, these results suggest that different vector
species might be co-distributed in the study area and
multiple infections by different P. vivax strains often
occur in individuals throughout the study area, which is
similar to the situation in Thailand [22].
Seroimmunological diagnosis, in particular by IFAT, is
an important tool for the detection of malaria, especially
when microscopic evidence of the parasites is not avail-
able due to the several reasons [23]. All patients had
antibodies against whole blood antigens of P. vivax by
IFAT. Among them, 94 cases (94%) had relatively high
antibody titres above 1:256. In patients who were
infected by P. falciparum, seven cases did not have anti-
bodies against whole blood antigens. These cases might
have been infected by P. falciparum recently. Addition-
ally, the 67 cases had antibody titres above 1:256. These
results indicate that most patients had been exposed to
both species (Table 3). The number of antibody positive
cases against VK247 (n = 25) antigen is similar to those
determined by DNA hybridization (n = 24). In ELISA,
Twenty-one cases showed mixed infection by VK210
and VK247, and 33 cases were positive for VK210 anti-
gen. This finding indicates that VK247 transmission has
actively progressed in Myanmar. There are 36 Anophe-
line mosquitoes in Myanmar [24], and there are differ-
ences in the sporozoite production of VK210 and
VK247 in each vector mosquitoes [21]. Therefore, inten-
sive field studies should be done in Myanmar to eluci-
date the relationship between P. vivax subtypes and
sporozoites production rates in each Anopheline mos-
quitoe for malaria control in Myanmar.
Conclusions
A major finding of this study was that the prevalence of
malaria in Myanmar is complex like elsewhere; these
data might be used as fundamental information for
molecular epidemiological and seroepidemiological stu-
dies in Myanmar. The geographic location of Myanmar
appears to contribute to the large diversity of P. vivax
g e n o t y p e sa n ds e r o t y p e si nt h i sc o u n t r y .M i g r a t i o no f
people within the country and between the neighbour-
ing countries may introduce a P. vivax population with
different alleles, thereby resulting in the complexity of
malaria parasites. Interallelic recombination between dif-
ferent parasite populations in the mosquito vector may
also facilitate genetic variation of P. vivax.F u r t h e rs t u -
dies using a large number of blood samples collected
from different geographic areas are required not only to
determine the nationwide parasite heterogeneity and
detailed malaria epidemiology in Myanmar but also to
implement malarial control programmes in the country.
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